Cytokinetics
CYTK · Biotechnology
$61.23
1.8%Ligand Pharmaceuticals
LGND · Biotechnology
$303.53
1.4%The short version
- Ligand Pharmaceuticals is the larger business, with $268M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 3.0 times as much.
- Cytokinetics grew revenue faster (376.6%, against 60.4%).
- Ligand Pharmaceuticals kept more of each dollar of sales as operating profit (15.3% operating margin, against −695.4% operating margin).
- Ligand Pharmaceuticals turned more of its sales into free cash flow (18.2% FCF margin, against −607.5% FCF margin).
| Latest fiscal year | CYTK · FY25 | LGND · FY25 |
|---|---|---|
| Size | ||
| Market cap | — | $6.6B |
| Revenue | $88.0M | $268M |
| Free cash flow | −$535M | $48.9M |
| Net income | −$785M | $125M |
| Growth | ||
| Revenue growth | 376.6% | 60.4% |
| 5-year growth | 9.5% | 10.4% |
| Share count change | — | 11.0% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | −695.4% | 15.3% |
| Net margin | −891.6% | 46.4% |
| FCF margin | −607.5% | 18.2% |
| Return on capital | — | 4.9% |
| Return on equity | — | 13.5% |
| Balance sheet | ||
| Net debt | −$912M | −$287M |
| Net debt / EBITDA | — | −3.8x |
| Dividends and buybacks | $0.0M | $15.0M |
| Valuation & quality | ||
| P/E | — | 32.3x |
| Piotroski F-score | — | 5 |
FY16
CYTK $106M
LGND $109M
FY17
CYTK $13.4M
LGND $141M
FY18
CYTK $31.5M
LGND $252M
FY19
CYTK $26.9M
LGND $120M
FY20
CYTK $55.8M
LGND $164M
FY21
CYTK $70.4M
LGND $242M
FY22
CYTK $94.6M
LGND $196M
FY23
CYTK $7.5M
LGND $131M
FY24
CYTK $18.5M
LGND $167M
FY25
CYTK $88.0M
LGND $268M
CYTK
LGND
FY16
CYTK 17.6%
LGND 40.3%
FY17
CYTK −848.3%
LGND 48.3%
FY18
CYTK −282.3%
LGND 65.1%
FY19
CYTK −368.0%
LGND 671.0%
FY20
CYTK −168.3%
LGND 22.9%
FY21
CYTK −264.5%
LGND 43.0%
FY22
CYTK −342.8%
LGND 1.6%
FY23
CYTK −6,589.7%
LGND 9.1%
FY24
CYTK −2,902.7%
LGND −13.5%
FY25
CYTK −695.4%
LGND 15.3%
CYTK
LGND
FY16
CYTK $35.4M
LGND $58.9M
FY17
CYTK −$105M
LGND $86.4M
FY18
CYTK −$102M
LGND $193M
FY19
CYTK −$93.5M
LGND −$31.9M
FY20
CYTK −$2.1M
LGND $50.1M
FY21
CYTK −$191M
LGND $70.0M
FY22
CYTK −$311M
LGND $120M
FY23
CYTK −$416M
LGND $46.1M
FY24
CYTK −$400M
LGND $95.2M
FY25
CYTK −$535M
LGND $48.9M
CYTK
LGND
FY16
CYTK —
LGND —
FY17
CYTK —
LGND —
FY18
CYTK —
LGND 30.0%
FY19
CYTK —
LGND 156.4%
FY20
CYTK —
LGND 6.9%
FY21
CYTK —
LGND 13.4%
FY22
CYTK —
LGND 0.2%
FY23
CYTK —
LGND 2.0%
FY24
CYTK —
LGND −2.1%
FY25
CYTK —
LGND 4.9%
CYTK
LGND
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.